Intuitive Surgical (NASDAQ:ISRG) Price Target Raised to $700.00

Intuitive Surgical (NASDAQ:ISRG) had its price objective boosted by Bernstein Bank from $655.00 to $700.00 in a research note released on Monday, MarketBeat.com reports. Bernstein Bank currently has an overweight rating on the medical equipment provider’s stock.

Several other analysts have also weighed in on ISRG. Royal Bank of Canada raised their price objective on Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a research note on Friday, October 18th. Leerink Partners lifted their price target on shares of Intuitive Surgical from $489.00 to $502.00 in a report on Thursday, October 17th. Piper Sandler reissued an “overweight” rating and issued a $670.00 price objective (up previously from $538.00) on shares of Intuitive Surgical in a research note on Friday, January 24th. Raymond James boosted their target price on shares of Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a research note on Friday, January 24th. Finally, The Goldman Sachs Group set a $604.00 price target on Intuitive Surgical in a research note on Friday, October 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus target price of $613.10.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $572.71 on Monday. The business has a fifty day moving average price of $548.70 and a two-hundred day moving average price of $507.04. The stock has a market capitalization of $203.99 billion, a PE ratio of 92.08, a PEG ratio of 5.19 and a beta of 1.39. Intuitive Surgical has a fifty-two week low of $364.17 and a fifty-two week high of $616.00.

Insider Transactions at Intuitive Surgical

In other news, insider Jamie Samath sold 22,903 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $525.00, for a total value of $12,024,075.00. Following the transaction, the insider now directly owns 8,757 shares of the company’s stock, valued at $4,597,425. The trade was a 72.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $539.00, for a total value of $202,664.00. Following the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,967,734. This represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,843 shares of company stock worth $15,357,560. Company insiders own 0.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Berbice Capital Management LLC bought a new stake in Intuitive Surgical in the fourth quarter valued at $26,000. Godsey & Gibb Inc. increased its position in Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 35 shares in the last quarter. MidAtlantic Capital Management Inc. acquired a new position in Intuitive Surgical during the 3rd quarter worth approximately $33,000. Decker Retirement Planning Inc. bought a new position in Intuitive Surgical in the fourth quarter worth approximately $36,000. Finally, Capital Performance Advisors LLP acquired a new stake in Intuitive Surgical in the third quarter valued at approximately $38,000. 83.64% of the stock is owned by institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.